Teva Pharmaceuticals USA - Meet Cory Wohlbach, who is responsible for steering Teva's new #biosimilar products through the regulatory approval process. Here he explains how biosimilars have the potential to reduce costs
![Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol | Business Wire Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol | Business Wire](https://mms.businesswire.com/media/20180212005322/en/640174/5/Boxes_With_Inhalers.jpg)
Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol | Business Wire
![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg)
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
![Teva Pharmaceutical Industries' new CEO Jeremy Levin speaks during a news conference in Tel Aviv May 9, 2012. Teva Pharmaceutical Industries posted a 40 percent jump in quarterly profit that beat estimates, Teva Pharmaceutical Industries' new CEO Jeremy Levin speaks during a news conference in Tel Aviv May 9, 2012. Teva Pharmaceutical Industries posted a 40 percent jump in quarterly profit that beat estimates,](https://c8.alamy.com/comp/2CX4Y3N/teva-pharmaceutical-industries-new-ceo-jeremy-levin-speaks-during-a-news-conference-in-tel-aviv-may-9-2012-teva-pharmaceutical-industries-posted-a-40-percent-jump-in-quarterly-profit-that-beat-estimates-boosted-by-robust-sales-of-its-own-branded-products-and-generic-medicines-in-the-united-states-reutersnir-elias-israel-tags-business-health-2CX4Y3N.jpg)
Teva Pharmaceutical Industries' new CEO Jeremy Levin speaks during a news conference in Tel Aviv May 9, 2012. Teva Pharmaceutical Industries posted a 40 percent jump in quarterly profit that beat estimates,
![Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA](https://www.fda.gov/files/styles/recall_image_small/public/7_1.jpg?itok=YhMegWXb)
Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA
![Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder](https://mms.businesswire.com/media/20200921005170/en/819864/4/Interactive_Media_Placeholder_webready.jpg)